BOADICEA has recently been extended to incorporate the associations between BRCA1 and BRCA2 mutations and other cancer risks (such as prostate cancer, pancreatic cancer and male breast cancer) [23], and has been shown to discriminate well between mutation carriers and noncarriers in a large series of families identified through UK genetic clinics [7,26]. Here, BRCA2 is linked to cancer.